The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT) in collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR) drafted up-to-date proposals for the management of antiplatelet therapy in patients undergoing elective invasive procedures. The proposals were discussed and validated by a vote; all proposals but one could be assigned with a high strength. The management of antiplatelet therapy is based on their indication and the procedure. The risk of bleeding related to the procedure can be divided into high, moderate and low categories depending on the possibility of performing the procedure in patients receiving antiplatelet agents (none,...
The contribution of platelets in the pathophysiology of thromboses has established antiplatelet ther...
Since 2011, data on patients exposed to direct oral anticoagulants (DOAs) while undergoing invasive ...
SummaryPerioperative management of anticoagulants and antiplatelet agents is based on a compromise b...
The French Working Group on Perioperative Haemostasis (GIHP)and the French Study Group on Haemostasi...
An increasing number of patients suffering from cardiovascular disease, especially coronary artery d...
An increasing number of patients suffering from cardiovascular disease, especially coronary artery d...
An increasing number of patients suffering from cardiovascular disease, especially coronary artery d...
Gestion péri-interventionnelle des nouveaux agents antiplaquettaires SCHNYDER-JORIS, Coralie, et al....
Management of antiplatelet agents before elective surgery To consider antiplatelet agents during pre...
Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still...
Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still...
Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
The widespread use of metal stents and drug-eluting stents has shown the extent to which patients wi...
Objective: To summarize the available evidence about the perioperative management of patients who ar...
The contribution of platelets in the pathophysiology of thromboses has established antiplatelet ther...
Since 2011, data on patients exposed to direct oral anticoagulants (DOAs) while undergoing invasive ...
SummaryPerioperative management of anticoagulants and antiplatelet agents is based on a compromise b...
The French Working Group on Perioperative Haemostasis (GIHP)and the French Study Group on Haemostasi...
An increasing number of patients suffering from cardiovascular disease, especially coronary artery d...
An increasing number of patients suffering from cardiovascular disease, especially coronary artery d...
An increasing number of patients suffering from cardiovascular disease, especially coronary artery d...
Gestion péri-interventionnelle des nouveaux agents antiplaquettaires SCHNYDER-JORIS, Coralie, et al....
Management of antiplatelet agents before elective surgery To consider antiplatelet agents during pre...
Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still...
Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still...
Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
The widespread use of metal stents and drug-eluting stents has shown the extent to which patients wi...
Objective: To summarize the available evidence about the perioperative management of patients who ar...
The contribution of platelets in the pathophysiology of thromboses has established antiplatelet ther...
Since 2011, data on patients exposed to direct oral anticoagulants (DOAs) while undergoing invasive ...
SummaryPerioperative management of anticoagulants and antiplatelet agents is based on a compromise b...